NUVATION BIO INC (NUVB)

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nuvation Bio to Present at the Jefferies London Healthcare Conference

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Friday 10/11 Insider Buying Report: GRAL, NUVB

Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Nuvation Bio to Present at the Cantor Global Healthcare Conference

Commit To Buy Nuvation Bio At $2.50, Earn 19.8% Annualized Using Options

Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib

Friday 6/14 Insider Buying Report: NUVB, GXO

Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

NUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024

NUVB stock results show that Nuvation Bio beat analyst estimates for earnings per share the first quarter of 2024.

NUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nuvation Bio (NYSE:NUVB) just reported results for the first quarter of 2024.Nu...

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Commit To Buy Nuvation Bio At $2.50, Earn 17.2% Annualized Using Options

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer